Mahesh Raj Nepal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mahesh Raj Nepal has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Alex Sparreboom
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio
51 shared publications - Eric Daniel Eisenmann
The Ohio State University
47 shared publications - Sharyn D. Baker
The Ohio State University 1 Columbus, OH
47 shared publications - Anika T. Chowdhury
Division of Pharmaceutics and Pharmacology, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
46 shared publications - Kevin M. Huang
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio
46 shared publications - Thomas Drabison
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio
46 shared publications
Latest Publications
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Interaction of TL-895 with protein kinases. A, KINOMEscan of TL-895 (500 nmol/L) against 403 nonmutant kinases to determine a selectivity score S(35) of 0.015. B, Kinase profiling of TL-895 against BTK and BMX revealed EC50 values of 3.02 and 0.53 nmol/L, respectively. Data represent the mean values (symbols) and SD (error bars) of two independent experiments performed in duplicate. C, Bioluminescence resonance energy transfer (BRET) luciferase response of BTK and BMX in the presence of TL-895 in HEK293 cells expressing BTK- and BMX-NanoLuc Fusion Vector showing EC50 values of 6.8 and 1.6 nmol/L, respectively. Data represent mean values (symbols) and SD (error bars) of two independent experiments performed in duplicate.
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Interaction of TL-895 with protein kinases. A, KINOMEscan of TL-895 (500 nmol/L) against 403 nonmutant kinases to determine a selectivity score S(35) of 0.015. B, Kinase profiling of TL-895 against BTK and BMX revealed EC50 values of 3.02 and 0.53 nmol/L, respectively. Data represent the mean values (symbols) and SD (error bars) of two independent experiments performed in duplicate. C, Bioluminescence resonance energy transfer (BRET) luciferase response of BTK and BMX in the presence of TL-895 in HEK293 cells expressing BTK- and BMX-NanoLuc Fusion Vector showing EC50 values of 6.8 and 1.6 nmol/L, respectively. Data represent mean values (symbols) and SD (error bars) of two independent experiments performed in duplicate.
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Inhibition of OATP1B1 and OATP1B3 by TL-895. Inhibition of EβG transport by OATP1B1 (A) and CCK-8 transport by OATP1B3 (B) in the presence and absence of Varying concentrations of TL-895 in engineered HEK293 cells. Data represent mean values (symbols) and SD (error bars) of 2 independent experiments performed in triplicate.
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Inhibition of OATP1B1 and OATP1B3 by TL-895. Inhibition of EβG transport by OATP1B1 (A) and CCK-8 transport by OATP1B3 (B) in the presence and absence of Varying concentrations of TL-895 in engineered HEK293 cells. Data represent mean values (symbols) and SD (error bars) of 2 independent experiments performed in triplicate.
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Positive control inhibition of BTK and BMX in NanoBRET assay. BRET luciferase response of BTK and BMX in the presence of CTx-0294885 or dasatinib, respectively, in HEK293 cells expressing BTK- and BMX-NanoLuc Fusion Vector showing EC50 values of 30.1 nM and 4.0 nM, respectively.
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Positive control inhibition of BTK and BMX in NanoBRET assay. BRET luciferase response of BTK and BMX in the presence of CTx-0294885 or dasatinib, respectively, in HEK293 cells expressing BTK- and BMX-NanoLuc Fusion Vector showing EC50 values of 30.1 nM and 4.0 nM, respectively.
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Pharmacokinetic DDIs induced by TL-895 in mice
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Pharmacokinetic DDIs induced by TL-895 in mice
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
In vitro transport and transport inhibition by TL-895. Competitive counterflow of [3H]-EβG efflux in the presence or absence of TL-895 or unlabeled EβG in HEK293 cells overexpressing (A) OATP1B1 or (B) OATP1B3. Data represent mean values (bars) and SD (error bars) representative of four independent experiments performed in triplicate. Concentration-dependent inhibition of 8-FcA transport by TL-895 in HEK293 cells overexpressing (C) OATP1B1 or (D) OATP1B3. Data represent the mean values (symbols) and SD (error bars) of two independent experiments performed in triplicate. A two-way ANOVA was used to compare the main effects of concentration and treatment group on normalized intracellular radioactivity. **, P < 0.01 and ****, P < 0.0001.
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
In vitro transport and transport inhibition by TL-895. Competitive counterflow of [3H]-EβG efflux in the presence or absence of TL-895 or unlabeled EβG in HEK293 cells overexpressing (A) OATP1B1 or (B) OATP1B3. Data represent mean values (bars) and SD (error bars) representative of four independent experiments performed in triplicate. Concentration-dependent inhibition of 8-FcA transport by TL-895 in HEK293 cells overexpressing (C) OATP1B1 or (D) OATP1B3. Data represent the mean values (symbols) and SD (error bars) of two independent experiments performed in triplicate. A two-way ANOVA was used to compare the main effects of concentration and treatment group on normalized intracellular radioactivity. **, P < 0.01 and ****, P < 0.0001.
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Dependence of TL-895 pharmacokinetics on mouse strain, CYP3A genotype, TL-895 dose, and sex
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Dependence of TL-895 pharmacokinetics on mouse strain, CYP3A genotype, TL-895 dose, and sex
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Assessment of DDI liabilities induced by TL-895. Influence of TL-895 (3 mg/kg) on circulating concentrations of CDCA-24G (A), oral (20 mg/kg) pravastatin (B), or oral (30 mg/kg) gilteritinib in C57BL/6 mice (C) and NSG mice (D). Data represent mean values (symbols) and SD (error bars) using 4 or 5 animals per group.
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Assessment of DDI liabilities induced by TL-895. Influence of TL-895 (3 mg/kg) on circulating concentrations of CDCA-24G (A), oral (20 mg/kg) pravastatin (B), or oral (30 mg/kg) gilteritinib in C57BL/6 mice (C) and NSG mice (D). Data represent mean values (symbols) and SD (error bars) using 4 or 5 animals per group.
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Interaction of TL-895 with CYP3A4 and CYP3A4-mediated metabolism. Metabolism of TL-895 by CYP3A4 microsomes (A) and the influence of CYP3A deficiency [CYP(−/−)] on the circulating concentration of oral (3 mg/kg) TL-895 in mice (B; N = 5 per group). Influence of TL-895 (10 μmol/L) and the positive control inhibitor ketoconazole (10 μmol/L) on the disappearance of the CYP3A4 substrate triazolam (left Y-axis) and the formation of its metabolite OH-triazolam (right Y-axis) in the presence of CYP3A4 microsomes (C). In vivo ratio of OH-triazolam to parent triazolam recovery in C57BL/6 male mice with vehicle or TL-895 10 mg/kg oral administration (D; N = 6 per group). Microsome data represent mean values (symbols) and SD (error bars, if larger than the symbol) of experiments performed in triplicate. In vivo data represent mean values (symbols) and SE (error bars). A two-way ANOVA was used to compare the main effects of time and treatment group on the percentages of TL-895, triazolam, and OH-triazolam recovery. ****, P < 0.0001. WT, wild type.
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Interaction of TL-895 with CYP3A4 and CYP3A4-mediated metabolism. Metabolism of TL-895 by CYP3A4 microsomes (A) and the influence of CYP3A deficiency [CYP(−/−)] on the circulating concentration of oral (3 mg/kg) TL-895 in mice (B; N = 5 per group). Influence of TL-895 (10 μmol/L) and the positive control inhibitor ketoconazole (10 μmol/L) on the disappearance of the CYP3A4 substrate triazolam (left Y-axis) and the formation of its metabolite OH-triazolam (right Y-axis) in the presence of CYP3A4 microsomes (C). In vivo ratio of OH-triazolam to parent triazolam recovery in C57BL/6 male mice with vehicle or TL-895 10 mg/kg oral administration (D; N = 6 per group). Microsome data represent mean values (symbols) and SD (error bars, if larger than the symbol) of experiments performed in triplicate. In vivo data represent mean values (symbols) and SE (error bars). A two-way ANOVA was used to compare the main effects of time and treatment group on the percentages of TL-895, triazolam, and OH-triazolam recovery. ****, P < 0.0001. WT, wild type.
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
TL-895 is an orally administered protein kinase inhibitor in clinical development for the treatment of B-cell malignancies and various other blood and autoimmune disorders. In the early stages of drug development, limited data are available to assess off-target engagement and drug–drug interaction (DDI) liabilities, which may have profound effects on drug safety and efficacy. In this context, we characterized the kinase interaction profile of TL-895 and determined that the agent inhibits Bruton’s tyrosine kinase (BTK) and bone marrow kinase on chromosome X (BMX), with more potent inhibition of BMX than BTK in a kinase assay (IC50: 0.53 vs. 3.02 nmol/L) and a bioluminescence resonance energy transfer (BRET) assay (IC50: 1.6 vs. 6.8 nmol/L). We used in vitro and in vivo models to assess DDI liabilities and identified TL-895 as a substrate of the hepatic uptake transporter OATP1B1 and the enzyme CYP3A4. In vivo, coadministration of TL-895 did not increase plasma concentrations of the endogenous and xenobiotic OATP1B1 substrates chenodeoxycholic acid 24-acyl-β-D-glucuronide, pravastatin, and gilteritinib, which indicates that TL-895 is an unlikely perpetrator of OATP1B1-mediated DDIs. Consistent with hepatic microsomal studies, we found that plasma concentrations of TL-895 were increased by 1.8- and 4.6-fold, respectively, in male and female mice lacking all CYP3A isoforms. The pharmacokinetic profile of TL-895 was not significantly sexually dimorphic or strain-dependent at drug doses producing human-equivalent measures of systemic exposure. These collective findings signify an important contribution of OATP1B1 and CYP3A4 to the in vivo handling of the dual BTK/BMX inhibitor TL-895 and suggest the agent is an unlikely perpetrator of potentially deleterious DDIs in polypharmacy regimens.Significance:TL-895 is an investigational second-generation BTK inhibitor for the treatment of B-cell malignancies. We found that TL-895 undergoes hepatocellular uptake by OATP1B-type transporters in advance of extensive CYP3A-mediated metabolism but is unlikely to perpetrate pharmacokinetic DDIs that could compromise drug safety in the context of polypharmacy regimens.
- 12 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
TL-895 is an orally administered protein kinase inhibitor in clinical development for the treatment of B-cell malignancies and various other blood and autoimmune disorders. In the early stages of drug development, limited data are available to assess off-target engagement and drug–drug interaction (DDI) liabilities, which may have profound effects on drug safety and efficacy. In this context, we characterized the kinase interaction profile of TL-895 and determined that the agent inhibits Bruton’s tyrosine kinase (BTK) and bone marrow kinase on chromosome X (BMX), with more potent inhibition of BMX than BTK in a kinase assay (IC50: 0.53 vs. 3.02 nmol/L) and a bioluminescence resonance energy transfer (BRET) assay (IC50: 1.6 vs. 6.8 nmol/L). We used in vitro and in vivo models to assess DDI liabilities and identified TL-895 as a substrate of the hepatic uptake transporter OATP1B1 and the enzyme CYP3A4. In vivo, coadministration of TL-895 did not increase plasma concentrations of the endogenous and xenobiotic OATP1B1 substrates chenodeoxycholic acid 24-acyl-β-D-glucuronide, pravastatin, and gilteritinib, which indicates that TL-895 is an unlikely perpetrator of OATP1B1-mediated DDIs. Consistent with hepatic microsomal studies, we found that plasma concentrations of TL-895 were increased by 1.8- and 4.6-fold, respectively, in male and female mice lacking all CYP3A isoforms. The pharmacokinetic profile of TL-895 was not significantly sexually dimorphic or strain-dependent at drug doses producing human-equivalent measures of systemic exposure. These collective findings signify an important contribution of OATP1B1 and CYP3A4 to the in vivo handling of the dual BTK/BMX inhibitor TL-895 and suggest the agent is an unlikely perpetrator of potentially deleterious DDIs in polypharmacy regimens.Significance:TL-895 is an investigational second-generation BTK inhibitor for the treatment of B-cell malignancies. We found that TL-895 undergoes hepatocellular uptake by OATP1B-type transporters in advance of extensive CYP3A-mediated metabolism but is unlikely to perpetrate pharmacokinetic DDIs that could compromise drug safety in the context of polypharmacy regimens.